Clinical trials: Acoustic Neuroma
Vestibular Schwannoma
Vestibular Schwannoma - Radiosurgery or Expectation: V-REX.
The purpose of this study is to compare the outcome of patients with vestibular schwannomas in two groups of randomised to either radiosurgery or expectation.
- Trial name
- V-REX (NCT02249572)
- Testing
- gamma knife radiosurgery
- Where
- Norway
- Volunteers
- 100 people
- Sponsor
- Haukeland University Hospital
Vestibular Schwannoma
Vestibular Schwannoma Organoids
In standard of care regularly planned surgery, tissue will be obtained from patients who are suspicious for having vestibular Schwannoma (on MRI).
- Trial name
- NCT05786144
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- Maastricht Radiation Oncology
Vestibular Schwannoma
Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560
The purpose of this study is to see if there is benefit to using an IV contrast called AK-Fluor® and a microscope filter called YELLOW560 when surgically removing a vestibular schwannoma, Meningioma, Head and Neck Paraganglioma…
- Trial name
- NCT04351373
- Testing
- Fluorescein Sodium, YELLOW560 filter
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Growing Vestibular Schwannomas
A Study of Nilotinib in Growing Vestibular Schwannomas
Acoustic Neuromas (otherwise known as Vestibular Schwannoma -VS) are benign tumors which grow on the hearing nerve and can cause progressive hearing loss and compression of vital brain structures and even death if it continues.
- Trial name
- NCT01201538
- Testing
- Nilotinib
- Where
- 2 sites in Canada
- Volunteers
- 2 people
- Sponsor
- University Health Network, Toronto
Neuroma, Acoustic
Subtotal Resection of Large Acoustic Neuromas With Possible Stereotactic Radiation Therapy
The investigators study is to investigate safety and efficacy of performing a planned incomplete removal of large acoustic neuroma tumors to decrease surgical morbidity and yet avoid tumor recurrence by post-operative radiation…
- Trial name
- NCT01129687
- Testing
- Microsurgery, Stereotactic radiation therapy
- Where
- 9 sites in United States
- Volunteers
- 157 people
- Sponsor
- Stanford University
Neurofibromatosis Type 2, Vestibular Schwannomas
Exploring the Activity of RAD001 in Vestibular Schwannomas and Meningiomas
The primary objective is to estimate the proportions of vestibular schwannomas (VS) and meningiomas after 10 days of exposure to the study drug RAD001 at a dose of 10 mg daily, as determined by immunohistochemistry.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannomas, Meningiomas
- Trial name
- NCT01880749
- Testing
- RAD001
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- NYU Langone Health
Neurofibromatosis 2, Dermatology/Skin - Other
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
.Neurofibromatosis type 2 is an inherently autosomal dominant genetic disease, but cases of mosaicism or de novo mutation are not uncommon. the prevalence is estimated at 1 / 60,000.
- Trial name
- NCT03893643
- Testing
- no intervention
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
NF2-related Schwannomatosis, NF2
Luvometinib in Combination With Serplulimab for NF2-Related Tumors
This is an investigator-initiated, exploratory, multicenter, open-label, single-arm clinical trial and a substudy of the Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2).
- Conditions
- NF2-related Schwannomatosis, NF2, Neurofibromatosis Type 2, Vestibular Schwannoma
- Trial name
- NCT07708285
- Testing
- Luvometinib, Serplulimab
- Where
- 5 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing Tiantan Hospital
Schwannoma, Vestibular, Neurofibromatosis 2
NF2 Natural History Consortium
OBJECTIVES: I. Define the growth rates and clinical course of NF2-related tumors in patients with neurofibromatosis type 2. Associate growth rate with physical function.
- Conditions
- Schwannoma, Vestibular, Neurofibromatosis 2, Meningioma
- Trial name
- NCT00004483
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- House Ear Institute
Meningioma, Glioblastoma
Pilot Study Evaluating Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Intracranial Lesions During Neurosurgical Procedures
This pilot clinical study evaluates the safety and imaging performance of panitumumab-IRDye800 (pan800), a fluorescent, EGFR-targeted imaging agent - in patients undergoing neurosurgical resection of intracranial lesions.
- Conditions
- Meningioma, Glioblastoma, Acoustic Neuroma, Brain Cancer
- Trial name
- NCT07493447
- Testing
- Panitumumab-IRDye800
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Eben Rosenthal
Deafness
Intraoperative Electrically-evoked ABRs in Patients Undergoing Vestibular Schwannoma Surgery
This is a study of the feasibility of activating the auditory system by an electrode in direct contact with the cochlear nerve.
- Trial name
- NCT05248113
- Testing
- Electrical stimulation of cochlear nerve
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of California, Irvine
Vestibular Schwannoma
Secondary Endolymphatic Hydrops and Vestibular Schwannomas on 3 Tesla MRI
Endolymphatic hydrops is well known of the lay public in its primary form that is Ménière disease. Nowadays, the best w ay to approach it in vivo, is to use magnetic resonance imaging (MRI).
- Trial name
- NCT03593577
- Where
- France
- Volunteers
- 185 people
- Sponsor
- University Hospital, Strasbourg, France
Advanced Malignant Neoplasm, Castleman Disease
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
This phase I trial studies the side effects and best dose of bevacizumab and temsirolimus alone or in combination with valproic acid or cetuximab in treating patients with a malignancy that has spread to other places in the body…
- Conditions
- Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease
- Trial name
- NCT01552434
- Testing
- Bevacizumab, Cetuximab, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 154 people
- Sponsor
- M.D. Anderson Cancer Center
Vestibular Schwannoma, Brain Metastases
Protocol for Evaluating a Planning Algorithm for Gamma Knife Radiosurgery
The process of developing Gamma Knife radiosurgery treatment plans is today very dependent on the level of human expertise resulting in a great heterogeneity of the intrinsic qualities of the treatment planning and the quality of…
- Conditions
- Vestibular Schwannoma, Brain Metastases, Para-optic Meningioma
- Trial name
- SPEED (NCT03520829)
- Testing
- Intuitive Plan
- Where
- France
- Volunteers
- 30 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
Neurofibromatosis Type 2, Vestibular Schwannoma
WES of NF2-associated in Comparison to Sporadic Vestibular Schwannomas - Correlation With Clinical Data
Whole exome sequencing (WES) of 50 sporadic and 50 Neurofibromatosis Type2 (NF2)-associated vestibularis schwannomas (VS) in children and young adults.
- Conditions
- Neurofibromatosis Type 2, Vestibular Schwannoma, Acoustic Neuroma
- Trial name
- NF2 (NCT03210285)
- Testing
- Whole exome sequencing
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- University Hospital Tuebingen
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Acute Unilateral Vestibular Deafferentiation
Unravelling Risk Factors for Chronic Dizziness in Patients After an Acute Unilateral Vestibular Deafferentiation.
In many patients with an acute unilateral vestibular deafferentiation (uVD) syndrome symptoms are expected to resolve spontaneously because of central compensation.
- Trial name
- Activation (NCT04979598)
- Testing
- Home exercise program
- Where
- Belgium
- Volunteers
- 103 people
- Sponsor
- Universiteit Antwerpen
Neurofibromatosis Type 2, NF2
Selumetinib for NF2-Related Schwannomatosis
The goal of this clinical trial is to evaluate the efficacy and safety of the MEK1/2 inhibitor selumetinib in treating patients with neurofibromatosis type 2-related schwannomatosis (NF2-SWN), including both adults and children…
- Conditions
- Neurofibromatosis Type 2, NF2, NF2-related Schwannomatosis, Meningioma
- Trial name
- ASSIST (NCT07707947)
- Testing
- Selumetinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital
Quality of Life Outcomes, Acoustic Schwannoma
Quality of Life and Decisional Regret in Patients Affected by Acoustic Neuroma
Italian translation and validation study of two different questionnaire (VSQOL and DRS) about quality of life in patient with acoustic schwannoma.
- Trial name
- QOL-DR-NEUROMA (NCT06844461)
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Vestibular Schwannoma, Neurofibromatosis Type 2
Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an…
- Trial name
- Endostatin (NCT02104323)
- Testing
- Endostatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Beijing Tiantan Hospital